retatrutide dosing clinical trial retatrutide dose Reta data & — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP Retatrutide Dosage: 20 mg Vial

Members who engage with Nooms GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged

Clinical trials suggest significant weight reduction, though it is not yet approved for use

The gut microbiome's role in GLP-1 regulation is an active area of research, with emerging evidence suggesting that microbial diversity and specific bacterial strains may influence incretin hormone secretion, but more human studies are needed to establish clinical significance

Research consistently shows that higher-protein meals produce a greater GLP-1 response than lower-protein meals

Some of the most pronounced brain benefits found in the study related to reduced risks for psychosis and schizophrenia